BCL2L1 and lung cancer: Based on our data, patients with lung cancers that exhibit loss of function mutations in either CUL5, RNF7, UBE2F or Elongin B that coincide with high expression of MCL1/Bcl-xL could be good candidates for treatment with CDK9i or MCL1i.